Lexatumumab tolerated for pediatric solid tumors

October 16, 2012
Lexatumumab tolerated for pediatric solid tumors
Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric patients with solid tumors, according to a study published online Oct. 15 in the Journal of Clinical Oncology.

(HealthDay)—Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric patients with solid tumors, according to a study published online Oct. 15 in the Journal of Clinical Oncology.

Melinda S. Merchant, M.D., Ph.D., from the in Bethesda, Md., and colleagues conducted a phase I dose-escalation study to examine the safety, tolerability, pharmacokinetics, and immunogenicity of lexatumumab for recurrent or progressive solid tumors. Doses of 3, 5, 8, and 10 mg/kg were administered once every two weeks to 24 patients age 21 years of age and younger.

The researchers found that, over all four planned dose levels, the patients received a total of 56 cycles of lexatumumab. During the second cycle, one patient had grade 2 pericarditis consistent with radiation recall and one patient developed grade 3 pneumonia with hypoxia. For three to 24 cycles, five patients experienced stable disease. There were no complete or partial responses but evidence of antitumor activity was noted in several patients, including one patient with recurrent progressive osteosarcoma who experienced resolution of clinical symptoms and positron emission tomography activity, which was ongoing more than one year after cessation of therapy. There was a dramatic biomarker response seen in one patient with hepatoblastoma.

"In conclusion, this study demonstrates that lexatumumab is well tolerated in heavily pretreated pediatric patients with solid tumors," the authors write.

Explore further: Dose-escalated cetuximab tolerated in colorectal cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Dose-escalated cetuximab tolerated in colorectal cancer

July 5, 2012
(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience more grade ...

Chemo combination promising for multiple myeloma

May 2, 2012
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Bevacizumab active in HIV-linked Kaposi's sarcoma

March 20, 2012
(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

Tivozanib exhibits antitumor activity in renal cancer

April 10, 2012
(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma ...

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

BIND presents late-breaker clinical data at AACR on BIND-014's promising antitumor effects

April 4, 2012
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.